课题基金 / 基金详情

ACTG398 AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS IN COM

ACTG398 AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS IN COM
ACTG398 安普那韦作为 COM 中双蛋白酶抑制剂方案的一部分
批准号：
6306583
负责人：
GILDON N BEALL
金额：
$0.1万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6306583
关键词：
AIDS therapy HIV infections antiAIDS agent clinical research combination chemotherapy drug screening /evaluation human subject human therapy evaluation protease inhibitor

项目摘要

项目成果

GILDON N BEALL的其他基金

相似基金

相关文献

中文摘要
翻译
为了评估在常规治疗失败的患者中治疗艾滋病毒感染的策略。三联高效抗逆转录病毒(HAART)疗法目前正在非常广泛地使用，但在一些受试者中失败。这项研究将评估未能通过一到三次PI的受试者的几种治疗策略。将使用的新型治疗药物不能作为许可药物获得，尽管一些药物可以通过所谓的“扩大接触”机制获得。
英文摘要
To evaluate strategies for treatment of HIV infection in patient-subjects who have failed usual treatment.Triple drug, highly active antiretroviral (HAART) treatment is now being used very widely but it is failing in some subjects. This study will evaluate several treatment strategies in subjects that have failed one to three PI's. The novel treatment agents to be used are not available as licensed drugs, although some are available through so-called "expanded access" mechanisms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ACTG 328--RECOMBINANT HUMAN IL 2 BY IV OR SC IN HIV PATIENTS ON HAART
ACTG388 EFAVIRENZ OR NELFINAVIR IN COMBINATION W/ FIXED DOSE COMBINAT
PHYSIOLOGIC TESTOSTERONE REPLACEMENT IN HIV INFECTED WOMEN
PHASE I/II DOSING SAFETY AND ANTIVIRAL ACTIVITY OF HYDROSYUREA ALONE/COMBINED
海外基金